AI could play pivotal role in impending psychiatrist shortage

The United States is expected to experience a massive shortage of psychiatrists within the next five years. According to some researchers, however, AI technology could ease some of that burden.

One of those researchers, Peter Foltz of the University of Colorado Boulder, told Time magazine that AI’s ability to evaluate speech patterns and other data could speed up diagnoses and allow psychiatrists to monitor patients remotely. Foltz and colleagues published a study on this topic, “Using Machine Learning in Psychiatry: The Need to Establish a Framework That Nurtures Trustworthiness,” in Schizophrenia Bulletin on Nov. 1.

On the other hand, John Torous, MD, director of digital psychiatry at Beth Israel Deaconess Medical Center in Boston, told Time that developing effective algorithms in this area will be “an uphill challenge.”

“Artificial intelligence is only as strong as the data it’s trained on,” he said, as quoted by Time.

Click below for the full story:

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.